HTA collaboration in Europa
past, present and future perspectives

European network for Health Technology Assessment
Wim Goettsch, EUnetHTA JA3 directorate, Zorginstituut Nederland

EFHG Outcomes Event, Vienna, June 28, 2017
Content presentation

• Overview of current activities in Europa
• EUnetHTA
• Structural HTA collaboration after 2020
• Conclusion
EU cooperation on HTA

**Policy and strategic cooperation**
- Art 15 Directive 2011/24
- Set up October 2013
- Multiannual work programme
  - **Permanent**

**Scientific and technical cooperation**
- Started in the 1990’s, later EUnetHTA
- Now Joint Action 3 – **2016 – 2020**

**New HTA Initiative**
- Cooperation beyond 2020
- Inception Impact Assessment
- Description of the status quo
- Options for the future

Synergy and complementarity
EUnetHTA
Historical timeline

2006
- EUnetHTA Project
- Inception

2016
- Joint Action 1: Putting into practice
- Joint Action 2: Strengthening practical application
- Joint Action 3: Turning pilots into standard practice

EUnetHTA Collaboration
EUnetHTA JA3 (2016-2020)

Aims to build a sustainable model for the scientific and technical cooperation on Health Technology Assessment (HTA) in Europe

81 partners consisting of national, regional and non-for-profit agencies that produce or contribute to HTA

Project Coordinator:
Dutch National Health Care Institute (ZIN)
## Organisational and Governance Structure

<table>
<thead>
<tr>
<th>WP1 Network Coordination - Dutch Health Care Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>WP2 Dissemination</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EUnetHTA Assembly</th>
</tr>
</thead>
<tbody>
<tr>
<td>WP1 Network Coordination - Dutch Health Care Institute</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>WP1 Network Coordination - Dutch Health Care Institute</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
</tr>
<tr>
<td>United Kingdom</td>
</tr>
<tr>
<td>Finland</td>
</tr>
<tr>
<td>Malta</td>
</tr>
<tr>
<td>Italy</td>
</tr>
</tbody>
</table>

*HVB, LBI, GOEG, UMIT
Summary of select activities in JA3

WP4 Joint Production
• To produce 43 rapid REA on other technologies and 37 on pharmaceuticals
  • Two assessments on oncology products (midostaurin, regofarenib) are ongoing
  • To provide a system for topic selection and prioritization

WP5 Evidence Generation
• To conduct Early Dialogues (joint HTA or parallel/joint with regulators)
  • Early Dialogue WP (HAS, G-BA, NICE, AIFA (RER), NIPN, RIZIV/ZIN) has started
  • One joint parallel regulatory/HTA process will start this year
  • To link additional data collection to on-going activities

WP6 Quality Management
• To provide quality management for EUnetHTA joint products

WP7 National implementation and impact
• To facilitate the uptake of joint products at the national/local level
HTA in the life cycle of technologies

Use of technology in health care

Presenting and discussing requirements studies in ED*

Collecting evidence in development

Preparing submission files for EMA and HTA

Assessment for market authorization

Rapid REA

Additional data collection

Comparative or full HTA / REA

Time line of innovation

*Early dialogue
Stakeholder Involvement in JA3

1. Strategic involvement
   • Stakeholder pool in the HTA Network
   • Participation in the EUnetHTA Forum (Sept 14, 2017 (yearly interactions)

2. Participation in Work Packages
   • Information/knowledge on specific technical questions
   • Interaction on the level of specific activities like the Early dialogues and Joint Assessments (WP4)
   • Interaction on the level of methodologies, guidelines and procedures

3. Structural collaboration with EMA
   • One process for parallel early dialogue/scientific advice
   • Information sharing during REA and assessment for market authorization
   • Collaboration on additional data collection
Example: Rapid REA (Pharma)

Figure 1: Schematic overview of the organisation of the process of the pilots - General Overview

It should be noted that these graphs represent the ideal picture; however, divergence is very possible for specific joint REA’s.
# Structural EU HTA collaboration after 2020

## Policy options*

<table>
<thead>
<tr>
<th>Option 1</th>
<th>Option 2</th>
<th>Option 3</th>
<th>Option 4</th>
<th>Option 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Status quo – <strong>voluntary cooperation</strong></td>
<td><strong>Long-term voluntary cooperation</strong> (beyond 2020)</td>
<td>Cooperation through the collection, sharing and use of common tools and data</td>
<td>Cooperation on <strong>production of joint REA</strong> (relative effectiveness assessments) reports</td>
<td>Cooperation on production of <strong>joint Full HTA reports</strong> (REA+ economic)</td>
</tr>
<tr>
<td><strong>Non-legislative / voluntary</strong></td>
<td><strong>Legislative / voluntary + mandatory</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

+ Issues to be addressed

Conclusions

• Clear pathway from EUnetHTA JA3 to sustainable collaboration after 2020
  • Work according to a life-cycle approach
  • Joint REAs and parallel regulatory/HTA ED move out of pilot phase
  • Full interaction with stakeholders is pursued including interaction with the final decision makers/payers in order to increase implementation
  • Results consultation on post2020 scenario show preference for options 3/4
    • Cooperation to joint REA is voluntary but uptake is mandatory in case of participation

• Relevance for developments in Austria
  • European HTA collaboration will link to regional activities such as BeneluxA
  • Regional horizon scanning could also have additional value for European collaboration
  • Implementation of the EUnetHTA joint products in Austrian practice will have a focus in the coming period
Thank you

Any Questions?